Targeting autoantibody production to treat lupus
Official title: Silencing autoantibody secretion for SLE therapy
Funded at Larix Bioscience, LLC · NIH-10838510 · Data updated 2026-11-12
This study is testing a new treatment for people with Systemic Lupus Erythematosus (SLE) that aims to reduce harmful antibodies without affecting the immune cells that help protect against infections, making it a safer option for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Larix Bioscience, LLC NIH-funded |
| Lab location | 1 site (Sunnyvale, United States) |
| Project start | May 8, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $299,773 |
| NIH project number | 5R43AI172662-02 |
| Project ID | NIH-10838510 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Systemic Lupus Erythematosus who are experiencing issues related to autoantibody production.
✕Less likely to help
Patients with other autoimmune disorders or those who do not have Systemic Lupus Erythematosus may not benefit from this research.
What this research studies
This research focuses on developing a new therapy for Systemic Lupus Erythematosus (SLE), an autoimmune disorder characterized by harmful autoantibody production. The approach involves silencing the secretion of these autoantibodies without depleting B cells, which are essential for immune protection. By targeting a specific protein called CD79a, the therapy aims to inhibit the immune response that leads to autoantibody formation, potentially offering a safer treatment option for patients. This innovative method seeks to provide a reversible solution that maintains the patient's ability to fight infections while managing their autoimmune condition.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for patients with lupus, reducing harmful autoantibody levels without compromising their immune system.
How similar studies have gone: While the approach of targeting CD79a is innovative, similar strategies in autoimmune therapies have shown promise, suggesting potential for success.
Where this research is happening
-
Larix Bioscience, LLC
Sunnyvale, United States Active
Researchers
- Principal investigator: Mendelsohn, Andrew R — Larix Bioscience, LLC
- Study coordinator: Mendelsohn, Andrew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.